Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BPI-442096 in Advanced Solid Tumors
NCT05369312Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPI-442096 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and 1 more (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Adverse Events and Recommended Phase 2 Dose. Status: unknown.
02
Drugs
BPI-442096
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05369312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369312.